Banyu’s Elizabeth Cobbs on Merck’s Regulatory Policies in Japan: An Interview with PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
Banyu Pharmaceutical, a Japanese company established in 1915, after its founder discovered a remedy for syphilis, became a wholly owned subsidiary of Merck in 2004. Since then, Banyu has had a somewhat unique position in Japan as an affiliate of a global pharma company, but with strong Japanese roots. Elizabeth Cobbs, Banyu's senior director of public and industry policy, sat down with PharmAsia News' Tokyo bureau to discuss the company's strategic outlook and regulatory challenges.
You may also be interested in...
Merck Signs Licensing Deal With Santen, Marking Second Deal For Japan’s Top Ophthalmology Maker
Japan's Osaka-based Santen Pharmaceutical April 15 signed a worldwide licensing agreement with Merck for Tapros/Taflotan (tafluprost), a treatment for glaucoma and ocular hypertension
Merck Signs Licensing Deal With Santen, Marking Second Deal For Japan’s Top Ophthalmology Maker
Japan's Osaka-based Santen Pharmaceutical April 15 signed a worldwide licensing agreement with Merck for Tapros/Taflotan (tafluprost), a treatment for glaucoma and ocular hypertension
Policy Director Elizabeth Cobbs On Strategic Focus And Pipeline Of Banyu, And On Parent Merck, in Japan: An Interview with PharmAsia News, Part 1
Banyu Pharmaceutical, a Japanese company established in 1915, after its founder discovered a remedy for syphilis, became a wholly owned subsidiary of Merck in 2004. Since then, Banyu has had a somewhat unique position in Japan as an affiliate of a global pharmaceutical concern, but with strong Japanese roots. Elizabeth Cobbs, Banyu's senior director of public and industry policy, sat down with PharmAsia News' Tokyo bureau to discuss the company's strategic outlook and regulatory challenges.